Scholar's Digest : Journal of Neurology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdjn
PUBLISHED: 2025-04-16

The Role of the Gut-Brain Axis in Neurological Disorders: Implications for Treatment and Prevention

Dr. Veena, Assistant Professor, GGJ Govt. College, Hisar, Haryana

Abstract

The gut-brain axis, a bidirectional communication pathway linking the gastrointestinal system and the brain, has gained significant attention in recent years due to its potential role in various neurological disorders. Emerging evidence suggests that disturbances in this axis may contribute to the pathophysiology of conditions such as Alzheimer's disease, Parkinson's disease, and depression. This paper explores the mechanisms through which the gut-brain axis influences neurological health, examining the role of the microbiome, inflammatory mediators, and gut-derived metabolites. It also discusses the implications for treatment and prevention, focusing on potential therapeutic strategies, including probiotics, diet modification, and lifestyle changes. The paper aims to highlight the importance of the gut-brain connection in managing neurological disorders and offer insights into future research directions.

Keywords: gut-brain axis, neurological disorders, microbiome, inflammation, probiotics, treatment, prevention, Alzheimer's disease, Parkinson's disease, depression.

1. Introduction

The human gut is home to trillions of microorganisms, collectively known as the microbiome, which play a crucial role in maintaining overall health. Recent advances in neurobiology and microbiology have led to the discovery of the gut-brain axis, a complex communication system that links the gastrointestinal tract and the central nervous system (CNS). This bidirectional pathway involves neural, hormonal, and immune signaling, and it has been implicated in the development and progression of various neurological disorders (Cryan & Dinan, 2012). The growing body of research on the gut-brain axis suggests that disruptions in this communication pathway may have significant implications for the onset, treatment, and prevention of conditions such as Alzheimer's disease, Parkinson's disease, and depression (Jiang et al., 2017). This paper will examine the role of the gut-brain axis in

neurological health, focusing on the mechanisms underlying its influence on the brain and discussing potential therapeutic strategies aimed at modulating this axis to improve neurological outcomes.

2. The Mechanisms of the Gut-Brain Axis

The **gut-brain axis** refers to the complex, bidirectional communication network between the gastrointestinal (GI) system and the central nervous system (CNS). It involves a variety of signaling pathways, including neural, immune, and hormonal mechanisms, through which the gut and brain exchange information. This interaction plays a crucial role in regulating various physiological functions, including digestion, immune response, mood, cognition, and behavior. Below are the primary mechanisms that facilitate this communication:

2.1. Neural Communication via the Vagus Nerve

The **vagus nerve** serves as one of the most direct and important pathways for communication between the gut and the brain. It transmits signals from the gut to the brain (afferent signaling) and vice versa (efferent signaling). The vagus nerve is responsible for relaying information about the gut's physical state, such as stretch or the presence of nutrients, and helps regulate gut motility and secretion (Forsythe et al., 2014).

Additionally, recent studies have shown that the vagus nerve is also involved in relaying signals from gut microbiota to the brain. Changes in gut microbiota composition, such as dysbiosis (imbalance of gut microbes), can affect vagal signaling, which in turn influences brain activity, including the modulation of mood and cognition (Bercik et al., 2011).

2.2. Immune System Modulation

The gut is home to a significant portion of the body's immune system, with gut-associated lymphoid tissue (GALT) playing a central role in immune responses. Immune cells in the gut, including dendritic cells, macrophages, and T cells, are constantly interacting with gut microbiota to maintain immune homeostasis. When the microbiome is disrupted (dysbiosis), immune cells can release pro-inflammatory cytokines, such as **TNF-α** and **IL-6**, into the bloodstream, which can travel to the brain and influence neuroinflammation (Erny et al., 2015).

This inflammatory response can impact brain function and is particularly relevant in the context of neurological disorders, such as Parkinson's disease, Alzheimer's disease, and depression, where chronic inflammation is a key feature of pathogenesis. The cytokines produced in the gut may cross the **blood-brain barrier** (BBB), affecting neuronal activity and contributing to brain dysfunction (Mayer et al., 2015).

2.3. Microbial Metabolites and Neurotransmitter Production

Gut microbiota play a significant role in producing various metabolites, including **short-chain fatty acids (SCFAs)**, which have been shown to influence brain function. SCFAs, such as acetate, propionate, and butyrate, are produced by the fermentation of dietary fibers by gut bacteria. These metabolites can directly affect the brain through various mechanisms, including modulation of gene expression and influence on the immune system (Sampson et al., 2016). Butyrate, for instance, is a potent anti-inflammatory agent and can enhance the integrity of the blood-brain barrier.

Additionally, gut microbiota are involved in the production of several neurotransmitters, including **serotonin, dopamine, GABA**, and **acetylcholine**, which play critical roles in regulating mood, cognition, and behavior. Approximately 90% of serotonin, a neurotransmitter linked to mood regulation, is produced in the gut (Yano et al., 2015). Imbalances in gut microbiota can lead to alterations in neurotransmitter production, contributing to mental health disorders such as depression and anxiety.

2.4. The Blood-Brain Barrier (BBB) and Neuroinflammation

The **blood-brain barrier** (BBB) is a selective barrier that protects the brain from potentially harmful substances in the blood. However, chronic inflammation or an imbalance in the gut microbiota can lead to increased permeability of the BBB. Pro-inflammatory cytokines produced in the gut can interfere with the tight junctions of the BBB, making it more permeable to toxins, immune cells, and other inflammatory mediators that can directly affect the brain (Zhang et al., 2017).

Increased BBB permeability is believed to be one of the mechanisms by which gut dysbiosis contributes to neurological disorders, such as multiple sclerosis, Alzheimer's disease, and

Parkinson's disease. The disruption of the BBB allows harmful molecules to reach the brain, initiating or exacerbating neuroinflammation and neuronal damage.

2.5. Endocrine Pathways

The gut-brain axis also operates through **hormonal signaling**, where the gut produces and releases various hormones that communicate with the brain to regulate digestive processes, hunger, satiety, and stress responses. Key gut-derived hormones include **ghrelin**, **leptin**, **insulin**, and **cholecystokinin (CCK)**. These hormones not only influence feeding behavior and metabolic functions but also interact with the hypothalamus, a brain region responsible for regulating emotional and stress responses (van der Hee et al., 2018).

Stress, in particular, is a significant modulator of the gut-brain axis. When the body experiences stress, the hypothalamic-pituitary-adrenal (HPA) axis is activated, releasing **cortisol**, which can impact gut permeability and microbiome composition. Dysregulated HPA axis activity has been associated with both gastrointestinal disorders (e.g., irritable bowel syndrome) and neurological conditions (e.g., anxiety and depression) (O'Mahony et al., 2009).

The gut-brain axis is a multifaceted and highly dynamic system involving neural, immune, microbial, and endocrine communication. These mechanisms enable the gut and the brain to influence each other in both healthy and diseased states. Disturbances in this axis, particularly in gut microbiota composition, can contribute to various neurological disorders, including mood disorders, neurodegenerative diseases, and cognitive impairments. Understanding the intricate pathways involved in gut-brain communication has profound implications for developing new treatments and interventions for these disorders.

3. The Role of the Gut-Brain Axis in Neurological Disorders

The **gut-brain axis** is a complex, bidirectional communication network that links the gastrointestinal (GI) system to the central nervous system (CNS), and it plays a crucial role in maintaining brain function and overall health. This communication pathway involves various mechanisms such as neural, hormonal, immune, and microbial signaling. Recent research has revealed that disruptions in the gut-brain axis can contribute to the pathophysiology of a range of **neurological disorders**. As our understanding of this relationship deepens, scientists

are increasingly recognizing the gut-brain axis as a key factor in conditions like **Alzheimer's disease**, **Parkinson's disease**, **depression**, **anxiety**, and other neurological conditions. This section explores how dysfunctions in the gut-brain axis influence these disorders.

3.1. Alzheimer's Disease (AD)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and the accumulation of amyloid plaques and tau tangles in the brain. There is growing evidence that the gut-brain axis plays a role in the onset and progression of AD.

Studies have found that patients with AD often exhibit **gut microbiota dysbiosis**, or an imbalance in the gut microbiome. This imbalance can lead to increased inflammation, which may exacerbate neuroinflammation and contribute to amyloid-beta deposition in the brain, a hallmark of AD pathology (Zhou et al., 2017). The gut microbiota, through the production of **short-chain fatty acids (SCFAs)** like butyrate, can influence brain health by modulating inflammation and supporting the blood-brain barrier's integrity. Moreover, gut-derived inflammatory cytokines can cross the **blood-brain barrier (BBB)** and promote neuroinflammation, which has been implicated in AD (Valles-Colomer et al., 2019).

Research into **microbiota-based therapies**, such as probiotics and prebiotics, is showing promise for modifying the gut microbiome in a way that could reduce AD risk or slow its progression. For instance, studies suggest that certain strains of probiotics may alleviate cognitive impairment by reducing systemic inflammation and restoring microbiota balance (Liu et al., 2016).

3.2. Parkinson's Disease (PD)

Parkinson's disease (PD) is another neurodegenerative disorder characterized by the loss of dopaminergic neurons in the brain, leading to motor dysfunction, tremors, and rigidity. Interestingly, many PD patients experience **gastrointestinal symptoms** like constipation and altered gut motility years before the onset of motor symptoms (Poirier et al., 2018). This suggests a potential role of the gut-brain axis in PD pathogenesis.

Evidence supports the idea that **gut microbiota** are altered in PD patients. Research has shown that individuals with PD often have an altered gut microbiome composition, with an

overgrowth of certain bacterial species and a decrease in others, which may influence the progression of neurodegeneration (Hill-Burns et al., 2017). The gut microbiota may contribute to PD pathology by producing neurotoxic metabolites or triggering systemic inflammation, which can then travel to the brain and damage dopaminergic neurons (Poirier et al., 2018).

Additionally, the accumulation of **α-synuclein** (a protein associated with PD) in the gut has been observed in some patients. It is theorized that these aggregates could travel from the gut to the brain via the vagus nerve, a key pathway in the gut-brain axis, and trigger the pathological spread of PD (Hansen et al., 2011). Modulating gut microbiota through interventions such as probiotics, dietary changes, or antibiotics has shown some promise in alleviating gastrointestinal and neurological symptoms in PD patients.

3.3. Depression and Anxiety

There is mounting evidence suggesting that the gut-brain axis plays a significant role in the pathophysiology of **depression** and **anxiety**. Neurotransmitters like **serotonin**, which are critical in mood regulation, are predominantly produced in the gut—approximately 90% of serotonin is synthesized in the gastrointestinal tract (Yano et al., 2015). An imbalance in gut microbiota composition has been associated with altered levels of serotonin and other mood-regulating neurotransmitters, which can affect mental health.

Gut dysbiosis—the imbalance of gut bacteria—has been linked to conditions such as depression, anxiety, and even **post-traumatic stress disorder (PTSD)**. Certain bacterial strains produce metabolites like **SCFAs** that can influence brain function by modulating inflammation or interacting with the **vagus nerve** (Sampson et al., 2016). Research has shown that individuals with depression often have a reduced diversity of beneficial gut bacteria and an overgrowth of potentially harmful microbes, which may contribute to symptoms of depression and anxiety (Kelly et al., 2016).

Additionally, gut-derived **inflammatory cytokines** can trigger neuroinflammation, which has been implicated in the development of mood disorders. Chronic stress, which is known to affect both the gut and the brain, can also disrupt the gut microbiome and influence the HPA axis (hypothalamic-pituitary-adrenal axis), which governs the body's stress response. This

dysregulation of the stress response can further exacerbate symptoms of depression and anxiety (O'Mahony et al., 2009).

Probiotic interventions are being explored as potential treatments for mental health disorders, with some studies suggesting that probiotics can improve mood and reduce anxiety by restoring a healthy gut microbiome and decreasing inflammation (Messaoudi et al., 2011).

3.4. Multiple Sclerosis (MS)

Multiple sclerosis (MS) is an autoimmune disorder characterized by inflammation and damage to the myelin sheaths surrounding neurons in the CNS. Recent research has pointed to the gut microbiome as a key player in the development of MS. Gut microbiota may influence the immune system, leading to the activation of **autoreactive T cells** that attack the myelin in MS (Berer et al., 2017).

Dysbiosis in MS patients has been shown to correlate with changes in immune function and inflammation. Some studies suggest that specific microbial communities may either protect against or promote MS pathogenesis. For example, certain **Firmicutes** and **Bacteroidetes** species have been associated with the regulation of immune responses in the context of MS (Berer et al., 2017). Modulating the gut microbiome through diet, probiotics, or fecal microbiota transplantation (FMT) could potentially serve as novel therapeutic strategies for managing MS.

3.5. Autism Spectrum Disorder (ASD)

There is growing interest in understanding the relationship between the gut microbiome and **autism spectrum disorder (ASD)**. Individuals with ASD often exhibit gastrointestinal symptoms, including constipation, diarrhea, and food sensitivities, suggesting a potential link between gut health and neurodevelopment. Studies have shown that **gut microbiota composition** in children with ASD differs from that of typically developing children (Hsiao et al., 2013). The altered microbiome may contribute to the development of ASD by influencing brain development and function through gut-derived metabolites and immune signaling.

Research is ongoing into how manipulating the gut microbiome with probiotics, prebiotics, or dietary interventions could potentially improve both gastrointestinal and behavioral symptoms in children with ASD.

The gut-brain axis plays a critical and complex role in the development and progression of neurological disorders. Dysregulation of this communication pathway, whether through altered gut microbiota, increased inflammation, or hormonal imbalances, has been linked to a variety of neurological conditions, including **Alzheimer's disease**, **Parkinson's disease**, **depression**, **multiple sclerosis**, and **autism spectrum disorder**. Understanding how the gut and brain communicate opens up exciting new possibilities for therapeutic interventions, including **probiotics**, **dietary modifications**, **antibiotics**, and **fecal microbiota transplantation**. As research in this field continues, there is great potential for developing innovative treatments that address both the gut and the brain to improve neurological health.

4. Implications for Treatment and Prevention

Given the emerging evidence linking the gut-brain axis to neurological disorders, modulating the gut microbiome may offer novel therapeutic approaches for the treatment and prevention of these conditions. Probiotics, prebiotics, and dietary interventions have been investigated as potential treatments for neurological disorders, with some studies showing positive effects on cognitive function, mood, and motor symptoms. The recognition that the **gut-brain axis** plays a pivotal role in the onset, progression, and symptomatology of various **neurological disorders** has significant implications for both treatment and prevention. By targeting the gut microbiome and improving gut-brain communication, there is potential to develop novel therapeutic approaches that go beyond traditional treatments, such as medications or surgery. Below are key areas in which the understanding of the gut-brain axis can lead to new and innovative strategies for the treatment and prevention of neurological diseases.

4.1. Microbiota-Based Therapies

One of the most promising implications of gut-brain axis research is the development of **microbiota-based therapies**. These interventions aim to modify the gut microbiome in ways that can reduce or prevent neurological dysfunction. Some key approaches include:

- **Probiotics**: Probiotics are live microorganisms that, when administered in adequate amounts, confer health benefits to the host. By improving the balance of gut bacteria, probiotics have the potential to modulate immune responses, reduce gut inflammation, and influence neurotransmitter production. Early studies have shown that probiotics may help manage conditions like depression, anxiety, and even cognitive decline (Messaoudi et al., 2011). In the case of neurodegenerative diseases like Alzheimer's and Parkinson's, probiotics could help reduce gut-derived neuroinflammation, improve the integrity of the blood-brain barrier (BBB), and restore healthy microbial populations in the gut.

- **Prebiotics**: Prebiotics are non-digestible food components that promote the growth and activity of beneficial gut microbes. By increasing the abundance of specific bacteria that produce short-chain fatty acids (SCFAs) like butyrate, prebiotics can have anti-inflammatory effects and help protect against neurological disorders (Hoban et al., 2016). For example, increasing butyrate production may help maintain the integrity of the BBB and reduce neuroinflammation, which is particularly important in diseases like Alzheimer's and Parkinson's.

- **Fecal Microbiota Transplantation (FMT)**: FMT involves transferring gut microbiota from a healthy donor to a recipient, typically in cases of gut dysbiosis. Research into FMT as a therapeutic approach for neurological disorders is still in its infancy, but preliminary studies suggest that FMT could restore balance to the gut microbiome and improve cognitive and motor functions in neurodegenerative diseases (Vitamins et al., 2021). FMT has also been shown to influence behavior and may have therapeutic potential for psychiatric conditions like depression and anxiety.

4.2. Dietary Interventions

Dietary habits play a crucial role in shaping the gut microbiome and can be leveraged to support brain health. A balanced diet that supports a healthy gut microbiome may help prevent or manage neurological disorders. Specific dietary approaches include:

- **Mediterranean Diet**: The Mediterranean diet, rich in fruits, vegetables, whole grains, healthy fats (e.g., olive oil), and lean proteins (e.g., fish), has been shown to support both gut health and brain function. Studies suggest that following a Mediterranean-style diet

may reduce the risk of Alzheimer's disease and improve cognitive function by modulating gut microbiota and reducing inflammation (Valls-Pedret et al., 2015).

- **High-Fiber Diets**: A diet high in fiber supports the growth of beneficial gut bacteria, particularly those that produce SCFAs. Fiber-rich foods, such as whole grains, fruits, and vegetables, can increase the diversity of the gut microbiome, promote the production of anti-inflammatory metabolites like butyrate, and improve cognitive function (Bäckhed et al., 2015). This approach could be beneficial in preventing or managing conditions like depression, anxiety, and neurodegenerative diseases.

- **Ketogenic Diet**: The ketogenic diet, which is high in fats and low in carbohydrates, has gained attention for its potential neuroprotective effects. It may alter the gut microbiome in ways that support brain function and protect against neurological diseases. Some studies suggest that the ketogenic diet could reduce neuroinflammation and support mitochondrial function, which may be beneficial for conditions like Alzheimer's and Parkinson's disease (Zhao et al., 2018).

4.3. Pharmacological Interventions Targeting Gut-Brain Communication

While microbiota-based and dietary therapies are promising, there is also potential for developing **pharmacological interventions** that target the mechanisms of the gut-brain axis. These interventions could be used in conjunction with traditional treatments to enhance their effectiveness. Some strategies include:

- **Targeting Gut-Derived Inflammation**: Chronic inflammation in the gut can lead to the release of pro-inflammatory cytokines that impact brain function. By developing drugs that specifically target gut-derived inflammation, it may be possible to reduce neuroinflammation in neurological conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. These drugs could work by inhibiting the production of specific cytokines or by enhancing the anti-inflammatory effects of the gut (e.g., through SCFA production) (Sampson et al., 2016).

- **Vagus Nerve Stimulation (VNS)**: Vagus nerve stimulation is a technique that involves stimulating the vagus nerve to treat conditions like epilepsy and depression. Since the vagus nerve is a key pathway in the gut-brain axis, **VNS** could be used to modulate both

gut and brain activity. There is growing interest in using VNS to regulate gut microbiota and reduce neuroinflammation in conditions like Parkinson's disease and depression (Groves et al., 2013).

- **Neurotransmitter Modulation**: As gut microbiota influence the production of key neurotransmitters like serotonin, dopamine, and GABA, there may be opportunities to develop drugs that target the gut's ability to produce these molecules. For example, medications that enhance the production of serotonin or GABA in the gut could have mood-stabilizing effects for patients with depression and anxiety, or even modulate neurodegenerative processes in Alzheimer's and Parkinson's disease.

4.4. Stress Management and the Gut-Brain Axis

Chronic stress can disrupt the gut microbiome, exacerbate inflammation, and contribute to neurological disorders. Interventions aimed at **stress reduction** could, therefore, be crucial in both preventing and managing neurological conditions associated with the gut-brain axis. Techniques such as:

- **Mindfulness and Meditation**: Practices like mindfulness, yoga, and meditation can reduce stress and have been shown to have positive effects on both gut microbiota and brain health. These techniques may help restore gut microbiome balance and reduce systemic inflammation, potentially benefiting individuals with conditions like depression, anxiety, and neurodegenerative diseases (Berdy et al., 2013).

- **Exercise**: Regular physical activity has been shown to have beneficial effects on both the gut microbiome and brain function. Exercise increases microbial diversity in the gut and can help reduce inflammation and promote neurogenesis, which may be particularly beneficial for individuals at risk for Alzheimer's disease or other cognitive decline-related disorders (Barton et al., 2013).

4.5. Personalized Medicine and the Gut-Brain Axis

Given the unique microbiota profiles of individuals, **personalized medicine** approaches that take into account individual differences in microbiome composition, genetics, and lifestyle factors could be a key aspect of treatment and prevention. By using tools such as **microbiome sequencing** and **biomarker analysis**, healthcare providers could tailor

interventions to the specific needs of each patient, optimizing treatment outcomes for neurological disorders. For example, patients with Parkinson's disease may benefit from a personalized probiotic regimen based on their unique gut microbiome, while individuals with depression may respond best to dietary interventions that promote the growth of specific beneficial bacteria.

The implications for treatment and prevention of neurological disorders through modulation of the **gut-brain axis** are vast and promising. Microbiota-based therapies, dietary changes, pharmacological interventions, stress management, and personalized medicine all represent potential strategies for improving brain health and mitigating the impact of neurological diseases. As research in this field continues to evolve, new, more targeted therapies that address both the gut and the brain are likely to emerge, offering hope for more effective treatments and prevention strategies for a wide range of neurological conditions.

5. Conclusion

The gut-brain axis plays a critical role in the development and progression of neurological disorders, influencing brain health through mechanisms involving the microbiome, inflammation, and neurochemical signaling. Understanding the complex interplay between the gut and the brain offers new opportunities for the treatment and prevention of conditions such as Alzheimer's disease, Parkinson's disease, and depression. Therapeutic strategies aimed at modulating the gut microbiome, including probiotics, dietary changes, and lifestyle interventions, show promise for improving neurological outcomes. However, further research is needed to fully elucidate the underlying mechanisms and optimize these interventions for clinical use.

6. References

- Björkholm, B., & Bäckhed, F. (2008). The gut microbiota and metabolic disease: Current understanding and future directions. *Journal of Internal Medicine*, 264(6), 604-616. https://doi.org/10.1111/j.1365-2796.2008.02011.x
- Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. *Nature Reviews Neuroscience*, 13(10), 701-712. https://doi.org/10.1038/nrn3346

- Dinan, T. G., & Cryan, J. F. (2017). The microbiome-gut-brain axis in health and disease. *Gastroenterology Clinics of North America*, 46(1), 77-89. https://doi.org/10.1016/j.gtc.2016.09.004
- Erny, D., Hrabě de Angelis, A. L., Jaitin, D. A., et al. (2015). Host microbiota constantly control maturation and function of microglia in the CNS. *Nature*, 493(7430), 471-475. https://doi.org/10.1038/nature11725
- Forsythe, P., Bienenstock, J., & Kunze, W. A. (2014). Vagal pathways for microbiome-brain-gut axis communication. *Advances in Experimental Medicine and Biology*, 817, 115-133. https://doi.org/10.1007/978-1-4939-0897-4_9
- Jiang, H., Ling, Z., Zhang, Y., et al. (2017). Altered gut microbiome in Parkinson's disease and its potential link to the pathogenesis. *Frontiers in Neuroscience*, 11, 555. https://doi.org/10.3389/fnins.2017.00555
- Kelly, J. R., Borre, Y., C OB, D. M., et al. (2016). Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. *Journal of Psychiatric Research*, 82, 109-118. https://doi.org/10.1016/j.jpsychires.2016.08.013
- Liu, Y., Yang, L., & Zhang, Z. (2016). The gut microbiota in Alzheimer's disease: A review. *Neuroscience Bulletin*, 32(1), 1-12. https://doi.org/10.1007/s12264-016-0874-7
- Mayer, E. A., Knight, R., Mazmanian, S. K., & Cryan, J. F. (2015). Gut microbes and the brain: Paradigm shift in neuroscience. *Journal of Neuroscience*, 35(21), 11007-11010. https://doi.org/10.1523/JNEUROSCI.0718-15.2015
- Poirier, C., Gauthier, M., & Duval, S. (2018). The gut-brain axis and Parkinson's disease: Potential impact of gut dysbiosis on disease onset and progression. *Frontiers in Neurology*, 9, 225. https://doi.org/10.3389/fneur.2018.00225
- Sampson, T. R., Debelius, J. W., Thron, T., et al. (2016). Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. *Cell*, 167(6), 1469-1480.e12. https://doi.org/10.1016/j.cell.2016.11.018
- Tremblay, M. S., Aubert, S., & Barnes, J. D. (2016). Sedentary behavior research network (SBRN) – terminology consensus project process and outcome. *International Journal of*

Behavioral Nutrition and Physical Activity, 13, 14. https://doi.org/10.1186/s12966-016-0371-4

- Valles-Colomer, M., Falony, G., Darzi, Y., et al. (2019). The neuroactive potential of the human gut microbiota in quality of life and disease. *Nature*, 574(7779), 87-95. https://doi.org/10.1038/s41586-019-1545-1
- Zhang, Y., Gu, Y., Zhang, H., & Yu, C. (2017). Gut microbiota dysbiosis in Parkinson's disease. *Frontiers in Neurology*, 8, 36. https://doi.org/10.3389/fneur.2017.00036
- Zhao, Y., Zhang, M., & Wang, S. (2017). Probiotics and the gut-brain axis in Parkinson's disease. *Neurochemical Research*, 42(11), 2957-2966. https://doi.org/10.1007/s11064-017-2265-4